Sardi, S. Pablo
Sanofi (United States)
7 papers on CoChatORCID 0000-0001-9805-3677
Most cited papers
- Verified
Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders
Roy, K., Murtie, J. C., El-Khodor, B. F., Edgar, N., Sardi, S. P., Hooks, B. M., Benoit-Marand, M., Chen, C., Moore, H., O'Donnell, P., et al. (2007) · Proceedings of the National Academy of Sciences
Schizophrenia research and treatmentNeurogenesis and neuroplasticity mechanisms
Cited by 319
- Verified
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
Espay, A. J., Vizcarra, J. A., Marsili, L., Lang, A. E., Simon, D. K., Merola, A., Josephs, K. A., Fasano, A., Morgante, F., Savica, R., et al. (2019) · Neurology
Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments
Cited by 274
- Verified
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
Sardi, S. P., Viel, C., Clarke, J., Treleaven, C. M., Richards, A. M., Park, H., Olszewski, M. A., Dodge, J. C., Marshall, J., Makino, E., et al. (2017) · Proceedings of the National Academy of Sciences
Lysosomal Storage Disorders ResearchParkinson's Disease Mechanisms and Treatments
Cited by 203
- Verified
Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy
Kuo, S.-H., Tasset, I., Cheng, M. M., Diaz, A., Pan, M.-K., Lieberman, O. J., Hutten, S. J., Alcalay, R. N., Kim, S., Ximénez-Embún, P., et al. (2022) · Science Advances
Lysosomal Storage Disorders ResearchParkinson's Disease Mechanisms and Treatments
Cited by 153
- Verified
Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease
Rotunno, M. S., Lane, M., Zhang, W., Wolf, P., Oliva, P., Viel, C., Wills, A.-M., Alcalay, R. N., Scherzer, C. R., Shihabuddin, L. S., et al. (2020) · Scientific Reports
Parkinson's Disease Mechanisms and TreatmentsAdvanced Proteomics Techniques and Applications
Cited by 94
- Verified
GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease
Senkevich, K., Zorca, C. E., Dworkind, A., Rudakou, U., Somerville, E., Yu, E., Ermolaev, A., Nikanorova, D., Ahmad, J., Ruskey, J. A., et al. (2023) · Brain
Lysosomal Storage Disorders ResearchParkinson's Disease Mechanisms and Treatments
Cited by 40
- Verified
Towards an AI biomedical scientist: Accelerating discoveries in neurodegenerative disease
Roberts, K. F., Landsness, E. C., Reese, J., Elbert, D., Strobel, G., Wu, E., Chen, Y., Lai, A., Abrams, Z. B., Zhu, M., et al. (2026) · The Journal of Prevention of Alzheimer's Disease
Artificial Intelligence in Healthcare and EducationArtificial Intelligence Applications
Cited by 1
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free